A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Official Title

A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Summary:

The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in patients with programmed death-ligand 1 (PD-L1)-positive cervical cancer (metastatic and/or recurrent).

Trial Description

Primary Outcome:

  • Independent Review Committee (IRC)-Assessed Objective Response Rate (ORR)
Secondary Outcome:
  • Percentage of Participants With Adverse Events
  • IRC-Assessed Duration of Response (DOR)
  • IRC-Assessed Disease Control Rate (DCR)
  • Investigator-Assessed Best Clinical Response (BCR) Rate
  • Investigator-Assessed DOR
  • IRC-Assessed Progression-Free Survival (PFS)
  • IRC-Assessed PFS Rate at 6 Months
  • Overall Survival (OS)
  • OS Rate at 6 Months and 12 Months
  • Minimum Serum Concentration (Cmin) of Tiragolumab
  • Maximum Serum Concentration (Cmax) of Tiragolumab
  • Cmin of Atezolizumab
  • Cmax of Atezolizumab
  • Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab
  • Percentage of Participants With ADAs to Atezolizumab

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society